Centrum Medyczne Medyk Sp. z o.o.
- Address
- lock Available on a paid plan
Oncology – Advanced Breast Cancer Research
The site focuses on Neoplasms, specifically on hormone receptor‑positive and HER2‑negative locally advanced, unresectable or metastatic breast cancer. Current studies aim to test innovative combination regimens that pair an AKT pathway inhibitor with CDK4/6 inhibitors and endocrine therapy to improve patient outcomes.
- Combination therapy targeting AKT and cell‑cycle pathways
- Biomarker‑guided enrollment based on PIK3CA, AKT1, PTEN status
- Assessment of progression‑free survival as primary efficacy endpoint
With a team of 13 investigators, Centrum Medyczne Medyk in Rzeszow is contributing valuable data to advance treatment options for this breast cancer subtype.
Gastroenterology – Ulcerative Colitis Studies
In the area of Digestive System Diseases, the centre conducts trials on ulcerative colitis, evaluating new therapeutic agents designed to induce remission in patients with moderate to severe disease activity. The research seeks to enhance disease control while monitoring safety and patient‑reported outcomes.
- Evaluation of clinical response and remission rates
- Safety monitoring in an active disease population
- Impact on quality of life and daily functioning
The ongoing work at Centrum Medyczne Medyk reflects a commitment to improving care for individuals living with inflammatory bowel conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 22 therapeutic areas and 15 of 198 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 198 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1Janssen Cilag International5active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International15trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Medyk Sp. z o.o.
lock Showing 1 of 100 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 198 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 11 | Unknown | 2018-07-26 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.